摘要
急性肾损伤(Acute kidney disease, AKI)是一种发病率高、自然病程多样、预后不一的临床急危重症。目前,AKI检测的标准诊断工具仍然是血肌酐浓度和尿量。然而,其在早期诊断AKI和评判预后等方面存在不足,因此寻找并获得有潜力的AKI生物标志物可对临床实践有诸多帮助。一些新型AKI生物标志物,如趋化因子、血管紧张素原、骨桥蛋白等在评估AKI早期和预后方面具有应用前景。本综述总结了近年AKI的早期诊断及预后标记物方面的进展。
Acute kidney injury (AKI) is a clinical emergency with a high incidence, diverse natural history and variable prognosis. At present, the standard diagnostic tools for AKI detection remain serum creat-inine concentration and urine output. However, it is insufficient in early diagnosis of AKI and evalu-ation of prognosis, so finding and obtaining potential biomarkers of AKI can be of great help to clin-ical practice. Some novel AKI biomarkers, such as chemokines, angiotensinogen, osteopontin, etc., have application prospects in assessing the early stage and prognosis of AKI. This review summa-rizes the recent progress in early diagnosis and prognostic markers of AKI.
出处
《临床医学进展》
2022年第8期7154-7160,共7页
Advances in Clinical Medicine
